Predicting the impact of biocorona formation kinetics on interspecies extrapolations of nanoparticle biodistribution modeling

Nanomedicine

Volumn 10, Issue 1, 2015, Pages 25-33

  Sahneh, Faryad Darabi ^a,b   Scoglio, Caterina M ^a   Monteiro Riviere, Nancy A ^a   Riviere, Jim E ^a  

^a KANSAS STATE UNIVERSITY   (United States)

^b Kansas State University   (United States)

Author keywords

allometry; biocorona; in vitro in vivo correlation; interspecies extrapolation; nanomaterials; nanoparticle biodistribution

Indexed keywords

NANOMATERIAL; NANOPARTICLE; PROTEIN;

ALLOMETRY; ARTICLE; BASAL METABOLIC RATE; CIRCULATION TIME; COMPARTMENT MODEL; COMPUTER MODEL; DOG; ELECTRIC POTENTIAL; HALF LIFE TIME; HAPLORHINI; HUMAN; KINETICS; MOLECULAR EVOLUTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RETICULOENDOTHELIAL SYSTEM; RODENT MODEL; SPECIES; SPECIES COMPARISON; TARGET CELL; TISSUE DISTRIBUTION; ANIMAL; CHEMISTRY; PHARMACOKINETICS; SURFACE PROPERTY; THEORETICAL MODEL;

ANIMALS; HUMANS; KINETICS; MICE; MODELS, THEORETICAL; NANOPARTICLES; PHARMACOKINETICS; RATS; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 84921448964     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.60     Document Type: Article

References (26)

1. Lynch I, Cedervall T, Lundqvist M, Cabaleiro-Lago C, Linse S, Dawson KA. The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv. Colloid Interface Sci. 134, 167-174 (2007).
2. Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7, 779-786 (2012).
3. Monteiro-Riviere NA, Samberg ME, Oldenburg SJ, Riviere JE. Protein binding modulates the cellular uptake of silver nanoparticles into human cells: implications for in vitro to in vivo extrapolations? Toxicol. Lett. 220, 286-293 (2013).
4. Lesniak A, Fenaroli F, Monopoli MP, Aberg C, Dawson KA, Salvati A. Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. ACS Nano 6, 5845-5857 (2012).
5. Pozzi D, Colapicchioni V, Caracciolo G et al. Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between pegylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells. Nanoscale 6, 2782-2792 (2014).
6. Park K. Facing the truth about nanotechnology in drug delivery. ACS Nano 7, 7442-7447 (2013).
7. Riviere JE. Of mice, men and nanoparticle biocoronas: are in vitro to in vivo correlations and interspecies extrapolations realistic? Nanomedicine (Lond.) 8, 1357-1359 (2013).
8. Eliasof S, Lazarus D, Peters CG et al. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc. Natl Acad. Sci. 110, 15127-15132 (2013).
9. Riviere JE. Pharmacokinetics of nanomaterials: an overview of carbon nanotubes, fullerenes and quantum dots. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1, 26-34 (2009).
10. Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu. Rev. Pharmacol. Toxicol. 52, 481-503 (2012).
11. Boxenbaum H. Time concepts in physics, biology, and pharmacokinetics. J. Pharmacol. Sci. 75, 1053-1062 (1986).
12. Dell'Orco D. The importance of the protein corona for successful nanodevice design and delivery. J. Nanomed. Biother. Discov. 2, e107 (2012).
13. Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V. Time evolution of the nanoparticle protein corona. ACS Nano 4, 3623-3632 (2010).
14. Xia XR, Monteiro-Riviere NA, Riviere JE. An index for characterization of nanomaterials in biological systems. Nat. Nanotechnol. 5, 671-675 (2010).
15. Caracciolo G, Pozzi D, Capriotti AL et al. Evolution of the protein corona of lipid gene vectors as a function of plasma concentration. Langmuir 27, 15048-15053 (2011).
16. Dell'Orco D, Lundqvist M, Oslakovic C, Cedervall T, Linse S. Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS ONE 5, e10949 (2010).
17. Sahneh FD, Scoglio CM, Riviere JE. Dynamics of nanoparticle-protein corona complex formation: analytical results from population balance equations. PLoS ONE 8, e64690 (2013).
18. Dell'Orco D, Lundqvist M, Cedervall T, Linse S. Delivery success rate of engineered nanoparticles in the presence of the protein corona: a systems-level screening. Nanomed. Nanotech. Biol. Med. 8, 1271-1281 (2012).
19. Barran Berdon AL, Pozzi D, Caracciolo G et al. Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. Langmuir 29, 6485-6494 (2013).
20. Mortensen NP, Hurst G, Wang W, Foster CM, Nallathamby PD, Retterer ST. Dynamic development of the protein corona on silica nanoparticles: composition and role in toxicity. Nanoscale 5, 6372-6380 (2013).
21. Tenzer S, Docter D, Kuharev J et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8, 772-781 (2013).
22. Lundqvist M, Stigler J, Cedervall T et al. The evolution of the protein corona around nanoparticles: a test study. ACS Nano 5, 7503-7509 (2011).
23. Salvati A, Pitek AS, Monopoli MP et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 8, 137-143 (2013).
24. Lee HA, Leavens TL, Mason SE, Monteiro-Riviere NA, Riviere JE. Comparison of quantum dot biodistribution with a blood-flow-limited physiologically based pharmacokinetic model. Nano Lett. 9, 794-799 (2009).
25. Li L, Tang F, Liu H et al. In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. ACS Nano 4, 6874-6882 (2010).
26. Riviere JE, Scoglio CM, Sahneh FD, Monteiro-Riviere NA. Computational approaches and metrics required for formulating biologically realistic nanomaterial pharmacokinetic models. Comput. Sci. Discov. 6, 014005 (2013).